Catalog No. | HV571046 |
---|---|
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Host species | Humanized |
Isotype | IgG1-kappa |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A |
Concentration | 1mg/ml |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G, purified from cell culture supernatant. |
Accession | Q9NR61 & P15692 |
Form | Liquid |
Storage buffer | 0.01M PBS,pH7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -361°C. |
Alternate Names | Bispecific,ABT-165,PR-1283233,CAS:1791420-09-1 |
Background | Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer. |
Note | For research use only. Not for use in clinical or therapeutic applications. |
SEC-HPLC detection for Research Grade Dilpacimab.
Detects VEGFA in indirect ELISAs.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France